Brief: Shattuck Labs Announces Positive Initial Topline Data From Phase 1 A/B Dose Expansion Clinical Trial Of Sl-172154 With Azacitidine

Shattuck Labs

13/12/2023 12:31

Dec 13 (Reuters) - Shattuck Labs Inc  STTK.O :
    * SHATTUCK LABS ANNOUNCES POSITIVE INITIAL TOPLINE DATA FROM
ONGOING PHASE 1 A/B DOSE EXPANSION CLINICAL TRIAL OF SL-172154
WITH AZACITIDINE IN FRONTLINE HIGHER-RISK MYELODYSPLASTIC
SYNDROMES (HR-MDS) AND TP53 MUTANT (TP53M) ACUTE MYELOID
LEUKEMIA (AML) PATIENTS
    * SHATTUCK LABS INC - SL-172154 DEMONSTRATED AN ACCEPTABLE
SAFETY
AND TOLERABILITY PROFILE AS A MONOTHERAPY AND IN COMBINATION
WITH AZACITIDINE (AZA)
    * SHATTUCK LABS INC - OBSERVED 79% OBJECTIVE RESPONSE RATE
(ORR)
IN FRONTLINE HR-MDS PATIENTS, PRIMARILY WITH TP53 MUTATIONS
    * SHATTUCK LABS INC - INITIAL COMPLETE RESPONSE (CR)/MARROW
COMPLETE RESPONSE (MCR) RATE OF 64% IN TRIAL
    * SHATTUCK LABS INC - LOOK FORWARD TO PROVIDING ANOTHER
UPDATE BY
MID-YEAR 2024

Source text for Eikon:  ID:nGNX91bGD 
Further company coverage:  STTK.O 

 ((Reuters.Briefs@thomsonreuters.com;))